AriBioLab Co.,Ltd.

Research AriBioLab Co.,Ltd. (261780.KQ) on Bullrun: market cap KRW 104.96B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 104.96B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 104.96Bn/an/an/a

Dividend history

About AriBioLab Co.,Ltd.

AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster.

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Pharmicell Co., Ltd. (005690.KS) Kanaph Therapeutics Inc. (0082N0.KQ) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) Hyundai Bioscience Co., Ltd. (048410.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ)

Frequently asked questions

What is AriBioLab Co.,Ltd.'s market cap?

AriBioLab Co.,Ltd.'s market capitalization is KRW 104.96B.

What does AriBioLab Co.,Ltd. do?

AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally, an influenza vaccine for seasonal flu, recombinant MBL for infectious disease suppression, and a TB booster vaccine.